EVALUATION OF CHIP (IPROPLATIN) IN RECURRENT PEDIATRIC MALIGNANT SOLID TUMORS - A PHASE-II STUDY (PEDIATRIC ONCOLOGY GROUP)

R NITSCHKE; C PRATT; M HARRIS; J KRISCHER; TJ VIETTI; H GRIER; W KAMPS; S TOLEDANO

EVALUATION OF CHIP (IPROPLATIN) IN RECURRENT PEDIATRIC MALIGNANT SOLID TUMORS - A PHASE-II STUDY (PEDIATRIC ONCOLOGY GROUP)

R NITSCHKE, C PRATT, M HARRIS, J KRISCHER, TJ VIETTI, H GRIER, W KAMPS, S TOLEDANO

University of Groningen

Research output: Contribution to journal › Article › Academic › peer-review

3 Citations (Scopus)

Abstract

CHIP (325 mg/M2), a second generation cisplatin derivative, was administered intravenously every 3 weeks to 85 pediatric patients with recurrent sarcomas (19), osteosarcomas (20), neuroblastoma (23), germ cell tumors (10), and other malignant tumors (7). Thirty-eight of them had been previously exposed to cisplatin.

Partial remissions were only observed in 3 of 23 (13% SE = 7%) patients having neuroblastoma. Severe thrombocytopenia (65%) and neutropenia (35%) were the dose limiting factors.

Original language	English
Pages (from-to)	93-96
Number of pages	4
Journal	Investigational new drugs
Volume	10
Issue number	2
Publication status	Published - Jul-1992

Keywords

CHIP
PEDIATRIC MALIGNANCIES
RECURRENT PEDIATRIC MALIGNANT SOLID TUMORS
PHASE-II STUDY

Cite this

@article{4a14d81178a44f7b97b0fe2041f407c7,

title = "EVALUATION OF CHIP (IPROPLATIN) IN RECURRENT PEDIATRIC MALIGNANT SOLID TUMORS - A PHASE-II STUDY (PEDIATRIC ONCOLOGY GROUP)",

abstract = "CHIP (325 mg/M2), a second generation cisplatin derivative, was administered intravenously every 3 weeks to 85 pediatric patients with recurrent sarcomas (19), osteosarcomas (20), neuroblastoma (23), germ cell tumors (10), and other malignant tumors (7). Thirty-eight of them had been previously exposed to cisplatin.Partial remissions were only observed in 3 of 23 (13% SE = 7%) patients having neuroblastoma. Severe thrombocytopenia (65%) and neutropenia (35%) were the dose limiting factors.",

keywords = "CHIP, PEDIATRIC MALIGNANCIES, RECURRENT PEDIATRIC MALIGNANT SOLID TUMORS, PHASE-II STUDY",

author = "R NITSCHKE and C PRATT and M HARRIS and J KRISCHER and TJ VIETTI and H GRIER and W KAMPS and S TOLEDANO",

year = "1992",

month = jul,

language = "English",

volume = "10",

pages = "93--96",

journal = "Investigational new drugs",

issn = "0167-6997",

publisher = "SPRINGER",

number = "2",

}

TY - JOUR

T1 - EVALUATION OF CHIP (IPROPLATIN) IN RECURRENT PEDIATRIC MALIGNANT SOLID TUMORS - A PHASE-II STUDY (PEDIATRIC ONCOLOGY GROUP)

AU - NITSCHKE, R

AU - PRATT, C

AU - HARRIS, M

AU - KRISCHER, J

AU - VIETTI, TJ

AU - GRIER, H

AU - KAMPS, W

AU - TOLEDANO, S

PY - 1992/7

Y1 - 1992/7

N2 - CHIP (325 mg/M2), a second generation cisplatin derivative, was administered intravenously every 3 weeks to 85 pediatric patients with recurrent sarcomas (19), osteosarcomas (20), neuroblastoma (23), germ cell tumors (10), and other malignant tumors (7). Thirty-eight of them had been previously exposed to cisplatin.Partial remissions were only observed in 3 of 23 (13% SE = 7%) patients having neuroblastoma. Severe thrombocytopenia (65%) and neutropenia (35%) were the dose limiting factors.

AB - CHIP (325 mg/M2), a second generation cisplatin derivative, was administered intravenously every 3 weeks to 85 pediatric patients with recurrent sarcomas (19), osteosarcomas (20), neuroblastoma (23), germ cell tumors (10), and other malignant tumors (7). Thirty-eight of them had been previously exposed to cisplatin.Partial remissions were only observed in 3 of 23 (13% SE = 7%) patients having neuroblastoma. Severe thrombocytopenia (65%) and neutropenia (35%) were the dose limiting factors.

KW - CHIP

KW - PEDIATRIC MALIGNANCIES

KW - RECURRENT PEDIATRIC MALIGNANT SOLID TUMORS

KW - PHASE-II STUDY

M3 - Article

VL - 10

SP - 93

EP - 96

JO - Investigational new drugs

JF - Investigational new drugs

SN - 0167-6997

IS - 2

ER -